Jeffrey Bornstein

Jeffrey Bornstein

Company: Eledon Pharmaceuticals Inc.

Job title: Chief Medical Officer

Seminars:

– Evaluating a Next Generation Anti-CD40L Antibody as a Therapy for Patients with ALS 12:00 pm

The rationale for targeting CD40L in patients with ALS Results of a pilot study targeting CD40L in patients with ALS Looking to the future with targeting CD40L in patients with ALSRead more

day: Day Two AM

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.